类风湿关节炎皮下托珠单抗治疗:TOZURA共通框架4期研究项目在22个国家的发现
TOZURA为跨国、开放标签、单臂、共通框架4期研究项目(11项方案,22个国家),纳入1804例中重度类风湿关节炎患者,每周皮下注射托珠单抗162 mg至少24周,可单药或联合csDMARD。第24周两组DAS28-ESR均较基线显著下降(单药-3.40 vs 联合-3.46),组间无显著差异(P=0.46),疗效与安全性与已知特征一致。
要点
- 单药组与联合csDMARD组第24周DAS28-ESR较基线均显著下降,组间无显著差异。
- 两组达到DAS28-ESR、CDAI缓解及ACR 20/50/70/90应答的比例相似。
- 13.9%患者退出,5.8%发生至少一次严重不良事件(14.6/100患者年),死亡6例(0.64/100患者年)。
核心结论
- 该4期研究项目在22个国家11项研究的共通框架下,证实皮下托珠单抗单药与联合csDMARDs疗效相当,疗效与安全性与已知特征一致。
研究设计与样本
- TOZURA为跨国、开放标签、单臂、共通框架4期研究项目,含11项方案、22个国家。
- 共纳入1804例中重度类风湿关节炎患者,均每周皮下注射托珠单抗162 mg至少24周,由研究者决定单药或联合csDMARD。
- 采用倾向性评分匹配进行组间比较。
主要发现
- 1804例中单药组353例(19.6%),联合治疗组1451例(80.4%)。
- 两组DAS28-ESR自基线至第24周均显著下降,平均变化单药组-3.40 vs 联合治疗组-3.46,组间无显著差异(P=0.46)。
- 两组达到DAS28-ESR或CDAI缓解及ACR 20/50/70/90应答的比例相似。
- 总体13.9%患者退出,其中6.2%因安全性原因、1.6%因疗效不足退出。
- 5.8%患者发生至少一次严重不良事件(14.6/100患者年),发生死亡6例(0.64/100患者年)。
关键数值与推荐
- 皮下托珠单抗162 mg每周给药至少24周,由研究者决定单药或联合csDMARD。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this pooled analysis of the TOZURA study programme was to evaluate the efficacy and safety of subcutaneous tocilizumab (TCZ-SC) as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs) in patients with moderate to severe RA who had an inadequate response to csDMARD or anti-TNF agent therapy or who were MTX naïve. METHODS: TOZURA is a multinational, open-label, single-arm, common-framework, phase 4 study programme (11 protocols, 22 countries). Patients received TCZ-SC 162 mg each week for ⩾24 weeks, administered at the investigator's discretion, as monotherapy or in combination with a csDMARD. Efficacy, safety and immunogenicity were evaluated; propensity score-based matching was used for between-group comparisons. RESULTS: Of 1804 patients, 353 (19.6%) received monotherapy and 1451 (80.4%) received combination therapy. The 28-joint DAS using ESR (DAS28-ESR) in both groups decreased significantly from baseline to week 24 (mean change: monotherapy -3.40, combination therapy -3.46), with no significant difference between groups (P = 0.46). The proportion of patients who achieved DAS28-ESR or Clinical Disease Activity Index remission or ACR 20/50/70/90 responses was similar between groups. Overall, 13.9% of patients withdrew-6.2% for safety reasons and 1.6% for insufficient therapeutic response; 5.8% of patients experienced one or more serious adverse events [14.6/100 patient-years (PY)]; six deaths occurred (0.64/100 PY). CONCLUSION: In a common framework of 11 studies in 22 countries, this phase 4 study programme confirmed TCZ-SC's known efficacy and safety profile with comparable effects as monotherapy and in combination with csDMARDs. TRIAL REGISTRATION: ClinicalTrials.gov (http://www.clinicaltrials.gov) NCT01941940, NCT01941095, NCT01951170, NCT01987479, NCT01988012, NCT01995201, NCT02001987, NCT02011334, NCT02031471, NCT02046603 and NCT02046616.
引用
- Choy E, Caporali R, Xavier R, et al. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018. PMID: 29244149. doi:10.1093/rheumatology/kex443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。